Precision BioSciences DTIL 深 沪
已收盘 11-28 16:00:00 美东时间
5.44
+0.330
+6.46%
华盛通- 最 高5.44
- 今 开5.19
- 成交量 9.02万股
- 最 低 5.1101
- 昨 收 5.11
- 总市值 7211.70万
- 52周最高 8.82
- 市盈率 静 5.23
- 换手率 0.68%
- 52周最低 3.61
- 委 比 -30.51%
- 总股本 1325.68万
- 历史最高 710.10
- 量 比 0.57
- 振 幅 6.46%
- 历史最低 4.02
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多H.C. Wainwright Keeps Their Buy Rating on Precision BioSciences (DTIL)
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision B...
11-21 23:45
Precision BioSciences to Present Gene Editing Therapy for Chronic Hepatitis B at Hep-DART 2025
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today
11-19 20:03
Precision BioSciences Announces $70M Stock Offering
Precision BioSciences ( ($DTIL) ) just unveiled an announcement. On November 10...
11-12 22:28
Precision BioSciences launches $75M stock and warrant offering
Precision BioSciences (DTIL) on Monday reported an underwritten offering of about 10.8 million shares of its common stock, along with warrants to buy up to 5.4 million additional shares, at a combined...
11-11 15:41
Precision BioSciences Unveils Promising ELIMINATE-B Trial Results
Precision BioSciences ( ($DTIL) ) has provided an update. On November 10, 2025,...
11-11 06:57
Precision BioSciences' First-in-Class Gene Editing Therapy PBGENE-HBV Shows Dose-Dependent Antiviral Response And Evidence Of Viral DNA Editing In Phase 1 ELIMINATE-B Study, Offering Potential Path Toward Chronic Hepatitis B Cure; To Host Conference Call Tomorrow, November 11th At 8:00 am ET
PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking AASLD session at
11-11 06:25
Precision BioSciences shares are trading lower after the company reported worse-than-expected Q3 financial results.
Precision BioSciences shares are trading lower after the company reported worse...
11-04 00:51
Precision BioSciences Q3 EPS $(1.84) Misses $(1.34) Estimate, Sales $13.000K Miss $5.400M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(1.34) by 37.31 percent. This is a 18.22 percent increase over losses of $(2.25) per
11-03 20:01
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Precision BioSciences Opens First U.S. ELIMINATE-B Site At Massachusetts General Hospital, Actively Recruiting Chronic Hepatitis B Patients
Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple global clinical trial sites -Phase 1 ELIMINATE-B trial for PBGENE-HBV is progressing and on
10-07 19:16
